New company analysis estimates value of NeuroVive Pharmaceutical’s NASH-project at USD $35 million
Swedish news- and analysis service BioStock has published a new company analysis covering NeuroVive Pharmaceutical and its pre-clinical project NV556 within the common liver disease NASH. The analysis concludes that the asset, at a point where a drug candidate is ready for clinical phase I studies and out-licensing to a major pharmaceutical company, should be valued at approximately $35 million or the equivalent of SEK 312 million.
Part of NeuroVive Pharmaceutical’s business strategy is to identify potential partners early in the process for those of its projects which aim for broad indications such as the liver disease NASH. By striking licensing deals with projects as early as in the pre-clinical stage, the company aims to generate significant revenue streams and to reach a positive cash flow sooner. The development program NV556 fits well into this project category.
The BioStock analysis concludes that if NeuroVive manages to bring NV556 through pre-clinical testing and thus has a phase I asset avaliable for out-licensing later this year, a risk-adjusted net present calculation, with a number of base calculations which are described in detail in the full analysis report, results in a value of USD $35 million for a clinical phase I-ready asset at the end of 2017.
To estimate the potential value of an asset in a company portfolio, BioStock determines a risk-adjusted net present value (rNPV) which is the industry standard for most Big Pharma companies.
Download the full analysis report (PDF) here:
For inquiries regarding the analysis report contact Tobias Thornblad, Head of Analysis BioStock and CEO Monocl Strategy Services.
For inquiries about BioStock and BioStock's services contact Jonas Söderström, CEO and Editor BioStock.
BioStock is a Swedish news and analysis service based in Lund, which covers the Nordic Life Science sector.